Qu Biologics Granted European Patent for Use of Bacterial Compositions for the Treatment of Cancer
May 11, 2015 – Qu Biologics Inc.
Vancouver, British Columbia – May 11, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today that it has been issued European patent 2286832 for the use of bacterial compositions for the treatment of cancer.
The allowed claims of the patent cover the use of a wide range of attenuated bacterial formulations for the targeted treatment of cancers situated in a wide range of tissues, including: kidney, lung, bone, colon, prostate, breast and skin. This coverage complements the coverage in Qu Biologics’ earlier broad European patent, which covers the use of killed bacterial preparations in a similarly broad range of cancers.
Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, “Qu is a leader in the development of immunotherapies designed to restore innate immune function to treat cancer and other immune-related diseases. This important European patent and our growing international patent portfolio provide strong protection of our expanding list of clinical applications for our proprietary immunomodulators.” Dr. Gunn added, “Qu’s SSIs use killed bacterial components to stimulate the innate immune system. We believe this approach is key to addressing the underlying immune dysfunction in these important diseases, including cancer, Crohn’s disease and ulcerative colitis.”
About Qu Biologics
Qu Biologics is at the forefront of a paradigm shift in the way we treat cancer and other immune-related disease. Rather than blocking or stimulating a single specific receptor or pathway, the company’s Site Specific Immunomodulators (SSIs), a novel class of immunotherapies, aim to restore the body’s normal immune response. SSIs, which are derived from components of inactivated common bacteria, are designed to activate the body’s innate immune response and restore normal immune function in the targeted organ or tissue to reverse the chronic inflammation underlying many chronic diseases including cancer, inflammatory bowel disease and other immune-related conditions. The company is currently recruiting participants for a clinical trial in Crohn’s disease and a Phase 2a open-label clinical trial in recurrent non-small cell lung cancer to study SSI treatment. A clinical trial in ulcerative colitis has received Health Canada approval and will begin in Q2 2015.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.
Qu Biologics Inc. cautions you that statements included in this release that are not a description of historical facts may contain forward-looking statements. These forward-looking statements are only predictions and may involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.